RobertIHaddadMD

Oncology • Boston, MA

Head & Neck Cancer

Division Chief /Head and Neck Oncology Dana Farber Cancer Institute Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. Haddad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Haddad's full profile

Already have an account?

Office
450 Brookline Avenue
Dana Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-3090

Fax+1 617-632-4448

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1995 - 1998
St Joseph's University Medical SchoolClass of 1995

Certifications & Licensure

MA State Medical License 2001 - 2025
NH State Medical License 2024 - 2024
FL State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Boston Magazine Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2013

Clinical Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Start of enrollment: 2004 Aug 01
Completed
Phase 3
Randomized Amifostine For SCCHN Start of enrollment: 2003 May 01
Completed
Phase 2
Title XELOX FOR SALIVARY GLAND CANCERS Start of enrollment: 2004 Oct 01
Terminated
Phase 2
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2007 Jan 01
Completed
Phase 1
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Randomized Phase III Trial Comparing Sequential Therapy With TPF/ Chemoradiation (ST) to Cisplatinum-Based Chemoradiotherapy With Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell Cancer of the Head and Neck ("The Parad Start of enrollment: 2004 Aug 01
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers Start of enrollment: 2012 Sep 01
Unknown status
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Start of enrollment: 2019 Jun 11
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

511 citations
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with anal...
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
Oral Oncology. 2018-06-01
252 citations
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a rando...
Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, Robert I. Haddad, Makoto Tahara
The Lancet. Oncology. 2021-04-01
2675 citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas
The New England Journal of Medicine. 2016-10-08

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Other

Human papillomavirus associated head and neck cancer
Haddad RI
http://www.uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2013-04-15

Authored Content

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Press Mentions

Study Identifies Predictors of Immunotherapy Response in Head and Neck CancerApril 12th, 2018
Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related CancersApril 18th, 2017
Some Head and Neck Cancer Patients Benefit from Continued Checkpoint Inhibitor TreatmentApril 3rd, 2017
Join now to see all